Adlai Nortye Ltd. (NASDAQ:ANL – Get Free Report) saw a significant decrease in short interest in the month of January. As of January 15th, there was short interest totalling 3,000 shares, a decrease of 55.9% from the December 31st total of 6,800 shares. Based on an average trading volume of 16,200 shares, the short-interest ratio is presently 0.2 days.
Adlai Nortye Price Performance
Shares of Adlai Nortye stock remained flat at $2.05 on Thursday. 652 shares of the company traded hands, compared to its average volume of 12,129. Adlai Nortye has a 1-year low of $1.85 and a 1-year high of $17.48. The business has a 50-day moving average of $2.19 and a two-hundred day moving average of $2.48.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reaffirmed a “buy” rating and set a $9.00 price objective on shares of Adlai Nortye in a research report on Monday, November 11th.
Adlai Nortye Company Profile
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.
Featured Stories
- Five stocks we like better than Adlai Nortye
- Which Wall Street Analysts are the Most Accurate?
- NVIDIA’s Slide Continues: Can Retail Investors Stop the Fall?
- 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
- Microsoft Stock Breaks Trend, But It Doesn’t Matter—Here’s Why
- Stock Sentiment Analysis: How it Works
- How Value Investors Find Undervalued Stocks and Build Wealth
Receive News & Ratings for Adlai Nortye Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adlai Nortye and related companies with MarketBeat.com's FREE daily email newsletter.
